Lantheus announces corporate plans, CAD agent strategy

03/24/2013 | AuntMinnie.com (free registration)

Lantheus Medical Imaging said it is undertaking measures to cut costs, including decreasing internal research and development and obtaining a partner for the final development of its PET radiopharmaceutical for diagnosing coronary artery disease, 18F-flurpiridaz. The partner will help with the remainder of Phase III development and commercialization, Lantheus said.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC